ECE2023 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (159 abstracts)
Bexagliflozin in Patients with Type 2 Diabetes: Scoping Review of the Published Randomised Control Trials
Vivek Redkar 1 , Sagar Redkar 2 , Supriya Redkar 2 , Manohar Manohar 3 , Aniket Inamdar 3 , Deepak Jumani 4 , SV Kulkarni 5 , Shreya Das 6 , Rajarshee Das 7 & Muskan Arora 8
1Redkar Hospitals- Goa, Malwan and Redi & KIMS Karad, Malwan, India; 2Redkar Hospital, Dhargal, Goa, Goa, India; 3Ashwini Hospital, Akluj, Maharashtra, Akluj, India; 4My Best Doctor Clinic and JJ Hospital, Mumbai, Mumbai, India; 5Kharghar Diabetes Heart & Child Care Centre, Navi Mumbai, Mumbai, India; 6Smt Kashibai Navle Medical College Pune. Maharashtra, Pune, India; 7MGM Medical College Mumbai, Mumbai, India; 8Rajiv Gandhi Medical College, Thane, Maharashtra, Mumbai, India
Introduction: US Food and Drug Administration (FDA) has recently approved bexagliflozin, a new SGLT2 inhibitor. We examined the outcomes and metabolic effects of Bexagliflozin across the published Randomised Controlled Trials (RCCTs)
Methods: A comprehensive literature search was done to extract publications from Medline-PubMed and Cochrane library, since inception till January 20, 2023, then screened and reviewed by two independent reviewers. Data including, study title, year of publication, name of the journal, study design, and the evaluated outcomes were charted for evidence synthesis. Scoping review was performed according to PRISMA-SR checklist. We included only the RCCTs for evaluation.
Results: We analysed 12 publications, and evaluated five RCCTs, with 1704 T2DM cumulatively contributing to the evidence base for Bexagliflozin. The mean duration of the trials (weeks) was 50(±42, minimum 12, maximum 96, 95% CI -1.6 to 102). The mean number of T2DM evaluated across RCCTs were 341(±62, minimum 288, maximum 426, 95% CI 264 to 418). Each of the RCCT has been distinct from each other for comparison with glimepiride, dose finding study, evaluation as monotherapy, comparison with sitagliptin and evaluation in patients with CKD stage 3a or 3b. The findings include, that bexagliflozin was noninferior to glimepiride in lowering HbA1c, was superior to glimepiride for decreases in body mass and SBP, and was associated with significantly fewer hypoglycaemic events than glimepiride; bexagliflozin confers substantial and dose-dependent benefits, is non-inferior to sitagliptin and provides benefits over sitagliptin in FPG and body mass. The results support the usage in patients with CKD stage 3a/3b CKD. The initial results of the Bexagliflozin Efficacy and Safety Trial (BEST) support the benefits in patients with high cardiovascular risk
Conclusions: The synthesis of the evidence from our analysis reflects that bexagliflozin has durable, clinically meaningful improvement in glycaemic control.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more